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Abstract
Acrylamide is a probable human carcinogen that was detected in several heat-treated foods, such as French fries and crisps,
in 2002. Prospective studies are needed on acrylamide and human cancer risk. We prospectively investigated the association
between acrylamide and gastrointestinal cancer risk. In 1986, 120,852 men and women (aged 55–69 y) were included in the
Netherlands Cohort Study on diet and cancer. At baseline, a random subcohort of 5000 participants was selected for a case-
cohort approach. Acrylamide intake was assessed with a FFQ at baseline and was based on acrylamide analyses in relevant
Dutch foods. After 13.3 y of follow-up, 2190, 563, 349, and 216 cases of colorectal, gastric, pancreatic, and esophageal
cancer, respectively, were available for analysis. The daily acrylamide intake of the subcohort was (mean 6 SD) 21.7 6
12.1mg. A 10-mg/d increment of acrylamide intake was associated with multivariable-adjusted Cox proportional hazard rate
ratios (HR) (95% CI) of 1.00 (0.96–1.06), 1.02 (0.94–1.10), 1.06 (0.96–1.17), and 0.96 (0.85–1.09) for colorectal, gastric,
pancreatic, and esophageal cancer, respectively. For former or never-smokers, the corresponding HR were: 1.03 (0.94–1.12),
1.09 (0.98–1.22), 1.07 (0.93–1.24), and 0.92 (0.76–1.11). There were some significantly increased risks within subgroups
stratified by obesity, nonoccupational physical activity, and age, factors that were a priori selected based on their capacity to
modify cytochrome P4502E1 activity. Overall, acrylamide intake was not associated with colorectal, gastric, pancreatic, and
esophageal cancer risk, but some subgroups deserve further attention. J. Nutr. 138: 2229–2236, 2008.
Introduction
In 2002, acrylamide was detected at high concentrations in heat-
processed, carbohydrate-rich foods, such as French fries and
potato crisps, and coffee (1). It is formed in Maillard browning
reactions in which amino acids, particularly asparagine, react
with reducing sugars at temperatures .120C (2,3).
Recently, in epidemiological studies, positive associations
have been observed for endometrial and ovarian cancer (4),
renal cell cancer (5), and postmenopausal estrogen receptor-
positive breast cancer risk (6). In a retrospective cohort study
from 1986 on occupational acrylamide exposure, a positive
association was observed between cumulative acrylamide expo-
sure and pancreatic cancer risk (7,8). These findings, combined
with the fact that acrylamide is present at high levels in many
everyday foods, stress the need for more prospective studies on
the association between dietary acrylamide and cancer risk.
In 1994, the International Agency for Research on Cancer
classified the industrial chemical acrylamide as a probable human
carcinogen based on its carcinogenic action in rodents (9). Animal
studies have shown positive dose-response relationships between
acrylamide exposure and cancer at multiple sites (10), e.g. oral
tissues, thyroid gland, mammary gland, lung, and skin. Both
genotoxic and nongenotoxic pathways have been suggested for
the carcinogenic effect of acrylamide. Acrylamide itself and its
epoxide metabolite glycidamide, which is generated by cyto-
chrome P4502E1, are clastogenic and glycidamide forms DNA
adducts. As for possible nongenotoxic pathways, acrylamide may
influence the redox status of cells and thus gene transcription or it
may interfere with DNA repair or hormonal balances (10).
Epidemiological studies on occupational acrylamide expo-
sure have been negative, apart from the positive association with
pancreatic cancer risk mentioned above (7,8,11–14). Despite the
recommendation of the WHO to perform epidemiological
studies on dietary acrylamide and cancer risk links (15), only a
few case-control studies (16–18) and prospective cohort studies
(4–6,19,20) have been published up to now. Most of these
studies rendered no indications for a positive association, except
for the 3 studies mentioned previously (4–6).
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Because the acrylamide molecule is small and hydrophilic, it
reaches everyorgan andvirtually every tissue in the body (21). For
this reason, theoretically all tissues are targets for carcinogenesis.
When acrylamide is taken orally, the gastrointestinal tract is
exposed to considerable amounts of this substance. Gastric and
pancreatic cancer have not been studied before, to our knowl-
edge, in epidemiological studies on dietary acrylamide intake.
Pancreatic cancer had our particular interest, because it was
associated with acrylamide exposure in 1 study on occupational
acrylamide exposure.
Subjects and Methods
Study participants. The Netherlands Cohort Study on diet and cancer
(NLCS) started in September 1986 with the inclusion of 58,279 men and
62,573 women aged 55–69 y sampled from Dutch municipal registries
(22). At baseline, the participants completed a self-administered ques-
tionnaire on diet and other cancer risk factors. The case-cohort approach
was used; cases were enumerated for the entire cohort, whereas the
accumulated person-years for the total cohort were estimated from a
subcohort of 5000 participants randomly sampled from the full cohort at
baseline. Since the start of the study, vital status information was
obtained from the subcohort at regular time intervals. Incident cases in
the total cohort were detected by annual record linkages to the regional
cancer registries and the Netherlands Pathology Registry. The complete-
ness of cancer follow-up was assessed to be at least 96% (23), whereas
the follow-up of the subcohort at the end of follow-up was nearly 100%
complete (only 2 male subcohort members were lost to follow-up). The
study was approved by the Medical Ethics Committees of the University
Hospital Maastricht and TNO Nutrition in February 1985 and July
1986, respectively. Further details on the design of the study and
methods of follow-up are presented elsewhere (22,24–26).
The analyses are based on 13.3 y of follow-up (September 1986–
January 2000). There were 2740 colorectal [1818 colon (ICD-O-3 C18),
278 rectosigmoid (ICD-O-3 C19), and 644 rectal (ICD-O-3 C20)] cancer
cases. Among the 681 gastric cancer cases, 180 adenocarcinomas of the
cardia (ICD-O-3 C16.0), 284 adenocarcinomas of the distant stomach
(ICD-O-3 C16.1-C16.5), and 217 adenocarcinomas of the stomach with
an unspecified localization (ICD-O-3 C16.6-C16.9) were detected. Of
the 445 pancreatic cancer cases (ICD-O-3 C25, excluding C25.4), 289
cases were microscopically verified. Among the 267 esophageal cancer
cases (ICD-O-3 C15), there were 142 adenocarcinomas (M8140–8141,
8190–8231, 8260–8263, 8310, 8430, 8480–8490, 8560, 8570–8572)
and 108 squamous cell carcinomas (M8050–8076).
Cases and subcohort members were excluded from analysis if they
had cancer (other than skin cancer) at baseline and if their dietary data
were incomplete or inconsistent (25) (Fig. 1).
Acrylamide intake assessment. The 150-item FFQ queried the
habitual intake of foods during the year preceding baseline (25).
The acrylamide intake was estimated from the mean acrylamide level
of food items and the frequency of consumption and portion size of
foods. To be representative of our cohort, we used data on acrylamide
levels in foods on the Dutch market only. Further details of the intake
assessment, including levels of acrylamide in foods, are presented
elsewhere (4).
Statistical analysis. Some confounders were chosen a priori and some
were included in the models only if they changed age and sex-adjusted
hazard rate ratios (HR)ofacrylamide (expressedas the interval between the
10th and 90th percentiles of intake of the subcohort: 27 mg acrylamide/d)
by.10% (Supplemental Table 1). Smoking status, quantity, and duration
were always included in the models, because cigarette smoke is an
important acrylamide source. Smokers havebeen showntohaveonaverage
4 times higher levels of acrylamide-hemoglobin adducts, which is amarker
of internal dose of acrylamide, than nonsmokers (27,28). For this reason,
subgroup analyses were performed for never-smokers. For gastric,
pancreatic, and esophageal cancers, the number of never-smokerswas too
small and therefore it was decided to combine never-smokers and ex-
smokers who quit.10 y before the start of the study.
Scaled Schoenfeld residuals were used to test the proportional
hazards assumption. HR were obtained through Cox proportional
hazards regression with STATA software (package 9.2). Additional
variance introduced by sampling a subcohort from the cohort was taken
into account by estimation of standard errors using the robust Huber-
White sandwich estimator. Tests for trend were performed by fitting the
median acrylamide intake per quintile as a continuous variable.
To check for the influence of preclinical disease, the analyses were
also performed excluding the first 2 y of follow-up.
Effect modification by other variables was tested using Wald chi-square
tests. The variables that were tested for effectmodificationwere selected based
on their ability to modify the activity of cytochrome P4502E1 and are age,
diabetes,obesity, smoking,alcohol consumption,andphysical activity (29–32).
Results
The mean daily acrylamide intake of the subcohort was 21.7 6
12.1 mg. The most important dietary source of acrylamide in the
FIGURE 1 Flow diagram of subcohort members
and cases on whom the analyses are based.
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subcohort was coffee, which contributed on average 47% to the
acrylamide intake, whereas Dutch spiced cake, cookies, French
fries, andpotato crisps contributed15, 13, 8, and2%, respectively
(5). However, most of the variance of the acrylamide intake was
explained byDutch spiced cake (57%), followed by coffee (15%),
French fries (14%), potato crisps (5%), and cookies (3%) (5).
The characteristics of cases and subcohort are shown inTable
1. Cases were older at baseline than subcohort members. The
BMI of gastric cardia cancer, microscopically verified pancreatic
cancer, and esophageal adenocarcinoma cases was higher than
that of the subcohort but lower for squamous cell esophageal
cancer cases. Smoking was more prevalent among all cancer case
groups (except colon cancer) than among subcohort members,
and cases smoked more and for a longer period. For dietary
factors, cases consumed more alcohol than the subcohort,
especially squamous cell esophageal cancer cases. Fish con-
sumption was higher in the gastric and squamous cell esophageal
cancer cases than in the subcohort. Finally, gastric cardia cancer
TABLE 1 Baseline characteristics of cases and subcohort members: the NLCS, 1986–19991
Variable Subcohort Colon Rectum
Gastric
cardia
Gastric
noncardia
Pancreas
total
Pancreas-
mv2 E-AC3 E-SCC4
n5 4438 1696 591 163 264 407 268 132 98
Dietary variables
Acrylamide intake, mg/d 21.8 6 12.1 21.8 6 12.1 21.6 6 11.5 22.5 6 11.1 21.9 6 11.6 22.1 6 12.7 22.0 6 11.8 22.0 6 11.3 20.4 6 11.5
Acrylamide intake,
mgkg body weight21.d21
0.30 6 0.18 0.30 6 0.17 0.29 6 0.16 0.29 6 0.15 0.30 6 0.17 0.30 6 0.19 0.30 6 0.17 0.28 6 0.15 0.29 6 0.16
Coffee, g/d 537 6 271 526 6 257 571 6 269 627 6 272 597 6 284 572 6 302 589 6 319 613 6 322 547 6 258
Dutch spiced cake, g/d 4.9 6 9.0 5.1 6 9.4 4.1 6 8.4 4.1 6 7.7 3.9 6 7.6 4.5 6 8.9 4.1 6 8.1 3.0 6 6.2 4.8 6 9.8
Cookies, g/d 13.6 6 10.8 14.2 6 10.6 13.4 6 9.6 14.8 6 11.8 13.7 6 11.9 13.4 6 12.4 13.1 6 10.1 12.9 6 9.5 9.4 6 8.5
Potato crisps, g/d 0.43 6 1.83 0.42 6 1.73 0.41 6 1.61 0.48 6 1.30 0.56 6 1.97 0.44 6 1.66 0.37 6 1.44 0.41 6 1.31 0.14 6 0.38
French fries, g/d 5.6 6 12.6 5.3 6 11.9 5.7 6 11.1 5.0 6 11.0 5.2 6 12.3 5.7 6 14.0 6.4 6 14.7 7.9 6 11.1 5.3 6 10.4
Vegetables, g/d 194 6 83 189 6 82 201 6 92 182 6 78 185 6 83 202 6 87 204 6 89 191 6 85 187 6 74
Fruit, g/day 175 6 120 175 6 118 173 6 121 154 6 115 155 6 106 170 6 116 163 6 105 161 6 133 141 6 119
Dairy products, g/d 304 6 203 291 6 190 292 6 198 317 6 206 310 6 199 301 6 201 300 6 183 324 6 223 262 6 229
Meat, g/d 99 6 42 98 6 40 102 6 42 106 6 45 101 6 44 100 6 40 99 6 40 99 6 41 106 6 40
Fish, g/d 12.9 6 15.4 12.5 6 14.9 13.0 6 14.6 16.1 6 20.7 15.0 6 20.3 13.1 6 16.5 12.1 6 14.6 13.8 6 17.9 15.2 6 14.5
Tea,6 cups/d 2.8 6 2.1 2.8 6 2.0 2.6 6 2.1 2.3 6 2.0 2.7 6 1.9 2.7 6 2.2 2.7 6 2.2 2.4 6 2.5 2.7 6 2.5
Total energy intake, kJ/d 8051 6 2160 8018 6 2114 8395 6 2102 8642 6 2357 8449 6 2240 8127 6 2093 8231 6 2098 8541 6 2110 8185 6 2018
Carbohydrate, g/d 202 6 62 200 6 59 210 6 62 214 6 70 214 6 64 201 6 61 204 6 58 210 6 61 191 6 55
Saturated fat, g/d 33.3 6 11.5 33.2 6 11.4 34.0 6 11.0 35.3 6 13.3 34.9 6 12.2 33.5 6 10.6 34.0 6 10.5 34.6 6 11.3 31.9 6 10.8
Trans unsaturated fatty acid, g/d 2.9 6 1.5 2.9 6 1.5 2.9 6 1.3 3.0 6 1.7 3.1 6 1.6 2.9 6 1.6 3.1 6 1.6 3.2 6 1.6 2.6 6 1.3
Fiber, g/d 27.0 6 8.1 26.6 6 8.0 27.9 6 8.2 27.4 6 7.4 26.6 6 7.5 27.1 6 7.9 27.4 6 7.7 27.1 6 8.1 24.7 6 7.5
Vitamin B-6, mg/d 1.44 6 0.36 1.42 6 0.36 1.50 6 0.38 1.50 6 0.35 1.45 6 0.35 1.45 6 0.37 1.47 6 0.35 1.45 6 0.34 1.41 6 0.37
Alcohol, g/d 10.4 6 14.4 11.1 6 14.7 13.4 6 17.4 14.2 6 15.7 11.6 6 15.0 13.0 6 16.8 12.8 6 16.8 15.4 6 18.5 23.4 6 28.1
Nondietary variables
Age, y 61.4 6 4.2 62.5 6 4.1 61.9 6 4.0 61.6 6 4.0 62.9 6 4.1 62.3 6 4.1 61.8 6 4.0 61.9 6 4.1 62.8 6 4.0
BMI, kg/m2 25.0 6 3.1 25.2 6 3.1 25.1 6 3.0 25.8 6 3.0 25.0 6 3.2 25.4 6 3.3 25.8 6 3.2 26.2 6 3.4 24.3 6 3.6
Height, cm 171 6 9 172 6 9 173 6 8 175 6 7 172 6 7 172 6 8 172 6 8 174 6 7 171 6 8
Current cigarette smoking, % yes 28.3 22.9 29.9 37.4 39.8 38.6 39.9 31.1 53.1
Cigarettes, n/d 9.5 6 10.9 10.1 6 11.4 11.9 6 11.6 14.9 6 12.3 12.2 6 11.6 11.0 6 11.5 11.0 6 10.5 16.7 6 13.9 14.7 6 12.4
Years of smoking, n 20.2 6 18.2 20.7 6 18.0 24.2 6 17.9 29.7 6 16.0 27.9 6 18.6 24.8 6 18.4 25.1 6 18.4 28.3 6 16.3 29.4 6 18.2
NOPA,7 min/d 72 6 61 72 6 61 75 6 71 82 6 71 71 6 58 68 6 51 71 6 55 79 6 93 72 6 71
Education, %
Primary school 29.1 29.2 30.5 27.6 36.4 33.2 32.5 22.0 33.7
Lower vocational school 21.9 18.6 24.9 26.4 24.6 17.9 18.7 28.0 20.4
Intermediate vocational/high school 34.8 36.0 31.6 29.4 29.2 34.2 34.0 34.1 34.7
Higher vocational school/university 13.6 15.6 11.8 16.6 9.1 14.5 14.6 15.2 10.2
Family medical history, % yes
Colorectal cancer 5.5 9.7 8.3 5.5 8.0 9.6 10.1 6.8 3.1
Gastric cancer 6.6 6.9 7.3 8.0 13.3 8.1 7.5 10.6 8.2
Pancreatic cancer 0.9 1.1 1.0 3.1 0.8 2.2 1.9 1.5 0.0
Esophageal cancer 0.9 1.3 0.5 1.2 0.4 0.7 0.4 2.3 2.0
1 Values are means 6 SD, or percentages.
2 mv, Microscopically verified.
3 E-AC, Adenocarcinoma of the esophagus.
4 E-SCC, Squamous cell carcinoma of the esophagus.
5 n without missing values on any of the row variables. n varies across the rows due to varying numbers of missing values for the row variables.
6 1 cup ¼ 125 mL.
7 NOPA, Nonoccupational physical activity.
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and esophageal adenocarcinoma cases drank less tea than the
subcohort did. For the proportional hazards analysis, men and
women were combined, because there was no significant effect
modification by sex.
Overall, there were no indications for a positive association
between acrylamide intake and colorectal cancer risk (Table 2).
When the analyses were restricted to never-smokers, there was
a significantly increased HR in the 3rd quintile for colon and
rectal cancer combined and for colon cancer alone. There was
no linear dose-response relationship over the quintiles. For
rectal cancer, the HR for never-smokers were significantly
increased in the 2nd and 4th quintile, but again there was no
linear dose-response relationship. The results did not change
when the first 2 y of follow-up were excluded (results not
shown).
Acrylamide intake was not associated with total gastric
cancer, gastric cardia adenocarcinoma, or noncardia gastric
cancer risk overall (Table 3). When the analyses were restricted
to nonsmokers, there were some indications (P ¼ 0.26 and 0.19,
respectively) for a positive linear trend, both for cardia and
noncardia cancer risk. However, these associations weakened
further when the first 2 y of follow-up were excluded.
Acrylamide intakewas not associatedwith pancreatic (Table 4)
or esophageal cancer risk (Table 5). The same applies to the group
of nonsmokers and when the first 2 y of follow-up were excluded.
Reanalyzing the age- and sex-adjusted associations between
acrylamide and cancer risk by excluding only observations with
missing values on age and sex did not lead to other conclusions
than excluding persons with missing values on any of the
covariables in the multivariable-adjusted models. Therefore,
bias due to nonrandomness of the missing values on the
covariables is not likely.
There was no significant effect modification by any of the
studied variables for colorectal or gastric cancer. For micro-
scopically verified pancreatic cancer, there was significant effect
modification by obesity, with obese people having an increased
risk (95%CI) of 1.59 (0.87–2.89, n¼ 14) per 10-mg/d increment
of acrylamide intake (P for effect modification ¼ 0.04).
There was also effect modification (P ¼ 0.02) by obesity for
esophageal cancer, particularly adenocarcinoma (P ¼ 0.03), with
obese participants having a 55% (8–121%; n ¼ 20) and 90%
(15–214%; n ¼ 14) increased risk, respectively, for every 10-mg/
d increment of acrylamide intake. The acrylamide-associated
cancer risk was significantly increased in the subgroup with the
highest nonoccupational physical activity, although the test for
effect modification was never significant. This was observed for
colon cancer in never-smokers and for pancreatic cancer. There
were significantly decreased acrylamide-associated risks for
noncardia gastric cancer in nonsmokers and for squamous cell
esophageal cancer in the group with the lowest nonoccupational
physical activity.
Although there was no significant effect modification by age,
the oldest participants had a significantly decreased risk of rectal
cancer per 10-mg/d acrylamide intake, whereas the youngest
TABLE 2 Association between dietary acrylamide intake and colorectal cancer risk: the NLCS, 1986–1999
Overall Never-smokers
Cases, n PY,1 n HR (95% CI)2 HR (95% CI)3 Cases, n PY,1 n HR (95% CI)2 HR (95% CI)4
Colorectal cancer
Acrylamide intake (10 mg/d) 2190 47,417 1.00 (0.95–1.04) 1.00 (0.96–1.06) 717 17,944 1.01 (0.93–1.09) 1.03 (0.94–1.12)
Q1 465 9308 Ref (1.00) Ref (1.00) 140 3870 Ref (1.00) Ref (1.00)
Q2 425 9364 0.94 (0.80–1.12) 0.96 (0.81–1.15) 156 3597 1.24 (0.93–1.64) 1.25 (0.93–1.68)
Q3 450 9462 1.03 (0.87–1.22) 1.06 (0.89–1.27) 139 3283 1.32 (0.99–1.78) 1.37 (1.01–1.86)
Q4 407 9662 0.92 (0.77–1.09) 0.96 (0.80–1.14) 139 3595 1.18 (0.88–1.57) 1.22 (0.90–1.67)
Q5 443 9621 0.96 (0.82–1.14) 1.00 (0.84–1.20) 143 3599 1.13 (0.85–1.51) 1.19 (0.88–1.63)
P-trend 0.62 0.94 0.80 0.57
Colon cancer
Acrylamide intake (10 mg/d) 1505 47,524 1.01 (0.96–1.06) 1.03 (0.98–1.09) 529 17,980 1.02 (0.93–1.11) 1.04 (0.94–1.14)
Q1 315 9322 Ref (1.00) Ref (1.00) 105 3877 Ref (1.00) Ref (1.00)
Q2 283 9384 0.93 (0.77–1.12) 0.95 (0.78–1.15) 108 3604 1.14 (0.83–1.57) 1.13 (0.82–1.57)
Q3 313 9504 1.06 (0.88–1.28) 1.11 (0.91–1.35) 107 3283 1.37 (0.99–1.89) 1.42 (1.01–1.98)
Q4 275 9685 0.92 (0.76–1.12) 0.98 (0.80–1.20) 100 3615 1.13 (0.82–1.56) 1.18 (0.83–1.66)
Q5 319 9629 1.03 (0.85–1.24) 1.09 (0.89–1.33) 109 3602 1.15 (0.84–1.58) 1.21 (0.86–1.69)
P-trend 0.75 0.37 0.63 0.45
Rectal cancer
Acrylamide intake (10 mg/d) 510 47,707 0.97 (0.90–1.05) 0.97 (0.89–1.05) 141 18,064 0.97 (0.84–1.12) 1.02 (0.86–1.20)
Q1 94 9375 Ref (1.00) Ref (1.00) 21 3880 Ref (1.00) Ref (1.00)
Q2 117 9462 1.27 (0.95–1.70) 1.29 (0.96–1.74) 42 3638 2.20 (1.27–3.81) 2.34 (1.32–4.13)
Q3 105 9508 1.16 (0.86–1.57) 1.18 (0.86–1.61) 23 3299 1.45 (0.78–2.71) 1.56 (0.82–2.97)
Q4 106 9701 1.16 (0.86–1.57) 1.16 (0.85–1.60) 31 3626 1.74 (0.97–3.11) 1.90 (1.03–3.51)
Q5 88 9661 0.94 (0.69–1.28) 0.94 (0.67–1.31) 24 3620 1.26 (0.69–2.32) 1.48 (0.77–2.84)
P-trend 0.28 0.27 0.82 0.79
1 PY, Person years.
2 Adjusted for age and sex, same data set as multivariable-adjusted data set.
3 Adjusted for: age, sex, BMI, height, energy, fiber and vitamin B-6 intake, consumption of vegetables, fruits, dairy, meat, and alcohol, nonoccupational physical activity, smoking
status (current vs. not current), number of cigarettes per day, number of years of smoking, and family history of colorectal cancer.
4 Adjusted for: age, sex, BMI, height, energy, fiber and vitamin B-6 intake, consumption of vegetables, fruits, dairy, meat, and alcohol, nonoccupational physical activity, and family
history of colorectal cancer.
2232 Hogervorst et al.
 at Universiteit M
aastricht UB Randwijck - Verwerking on January 15, 2009 
jn.nutrition.org
D
ow
nloaded from
 
participants had a significantly increased acrylamide-associated
pancreatic cancer risk.
Discussion
Overall, this prospective cohort study does not give strong
support for the hypothesis that dietary acrylamide intake is
positively associated with gastrointestinal cancer risk.
The association between dietary acrylamide and colorectal
cancer risk was studied in 2 case-control studies and 1 prospective
cohort study (16,17,19). These studies found no indications of a
positive association either. In our study, the HR across the quintiles
for colorectal cancer in never-smokers did not increase linearly (or
follow any other clear dose-response relationship) and, thus, the
significantHR in someof the quintiles aremost likely due to chance.
The association between acrylamide intake and gastric
cancer risk has not been studied before. In the present study,
no clear indications for a positive overall association were
found. We found no association between dietary acrylamide
intake and overall pancreatic cancer risk, contrary to a study on
occupational acrylamide exposure (8,11). However, the analyses
were poorly adjusted for smoking and other risk factors in that
study, which may have biased the results. Furthermore, in an
update of this study with longer follow-up and better adjustment
for smoking, the acrylamide-associated risk was much reduced
and no longer significant (13).
There was no overall association between acrylamide intake
and esophageal cancer risk. This was also observed in the only
other study on it, which was a case-control study (16).
The genotoxic action of glycidamide (10) is often noted as the
predominant mechanism of carcinogenic action in acrylamide
cancer risk assessments. The fact that we did not observe an
overall association between acrylamide intake and the risk of
gastrointestinal tumors, but did observe positive associations
between acrylamide intake and endometrial and ovarian cancer
risk in a previous study, indicates that disturbance of hormonal
balances may also be at the basis of acrylamide carcinogenesis. If
acrylamide does indeed exert its carcinogenic effects through a
hormonal mechanism, that would explain why no clear overall
associations between acrylamide intake and gastrointestinal
cancer risk were observed in this study, because sex hormones do
not play as clear a role in the etiology of these tumors as they do
in the etiology of, e.g. endometrial and ovarian cancer.
The fact that a Danish study observed a positive association
between acrylamide hemoglobin adducts in the blood and
postmenopausal estrogen receptor-positive breast cancer (6) also
points toward an effect of acrylamide on hormonal pathways.
The currentprospective cohort studyhas some limitations.FFQ
have limitations, as discussed elsewhere (33), but they are the only
feasible way to assess dietary intake over a long time period in
large-scale epidemiological studies. The NLCS FFQ has proven to
be both valid (25) and reproducible (26) with regard to nutrients
that correlate with acrylamide, such as carbohydrates and fiber.
TABLE 3 Association between dietary acrylamide intake and gastric cancer risk: the NLCS, 1986–1999
Overall Never and former smokers
Cases, n PY,1 n HR (95% CI)2 HR (95% CI)3 Cases, n PY,1 n HR (95% CI)2 HR (95% CI)4
Gastric cancer
Acrylamide intake (10 mg/d) 563 49,317 1.03 (0.96–1.11) 1.02 (0.94–1.10) 250 29,586 1.08 (0.98–1.20) 1.09 (0.98–1.22)
Q1 104 9774 Ref (1.00) Ref (1.00) 20 6224 Ref (1.00) Ref (1.00)
Q2 114 9819 1.15 (0.86–1.54) 1.09 (0.81–1.47) 22 6213 1.19 (0.78–1.83) 1.16 (0.74–1.80)
Q3 113 9759 1.20 (0.89–1.60) 1.09 (0.81–1.48) 28 5240 1.44 (0.93–2.24) 1.50 (0.95–2.38)
Q4 120 10,024 1.27 (0.95–1.70) 1.18 (0.87–1.60) 25 5865 1.23 (0.79–1.91) 1.24 (0.78–1.98)
Q5 112 9941 1.13 (0.84–1.51) 1.06 (0.78–1.45) 25 6045 1.42 (0.94–2.15) 1.43 (0.92–2.24)
P-trend 0.49 0.77 0.14 0.16
Gastric cardia adenocarcinoma
Acrylamide intake (10 mg/d) 143 49,383 1.03 (0.90–1.16) 1.05 (0.91–1.20) 66 29,591 1.14 (0.96–1.34) 1.16 (0.97–1.39)
Q1 24 9782 Ref (1.00) Ref (1.00) 10 6224 Ref (1.00) Ref (1.00)
Q2 29 9845 1.24 (0.71–2.17) 1.25 (0.71–2.21) 14 6214 1.51 (0.65–3.47) 1.54 (0.65–3.68)
Q3 34 9770 1.45 (0.84–2.51) 1.44 (0.82–2.52) 13 5243 1.71 (0.72–4.07) 1.85 (0.72–4.72)
Q4 27 10,045 1.16 (0.66–2.06) 1.21 (0.66–2.20) 12 5865 1.47 (0.61–3.53) 1.61 (0.63–4.11)
Q5 29 9942 1.21 (0.70–2.12) 1.28 (0.70–2.35) 17 6045 1.77 (0.78–3.98) 1.85 (0.76–4.52)
P-trend 0.77 0.66 0.26 0.26
Distant (noncardia) gastric cancer
Acrylamide intake (10 mg/d) 238 49,332 1.01 (0.91–1.12) 0.99 (0.88–1.11) 104 29,591 1.04 (0.90–1.20) 1.06 (0.91–1.24)
Q1 50 9774 Ref (1.00) Ref (1.00) 21 6224 Ref (1.00) Ref (1.00)
Q2 43 9822 0.91 (0.60–1.39) 0.83 (0.54–1.30) 20 6214 1.03 (0.55–1.93) 1.00 (0.52–1.92)
Q3 43 9767 0.98 (0.64–1.51) 0.88 (0.57–1.38) 17 5243 1.15 (0.59–2.21) 1.26 (0.63–2.51)
Q4 58 10,027 1.33 (0.89–1.97) 1.19 (0.79–1.80) 21 5865 1.27 (0.68–2.36) 1.35 (0.70–2.60)
Q5 44 9941 0.94 (0.62–1.43) 0.88 (0.56–1.38) 25 6045 1.32 (0.73–2.39) 1.42 (0.75–2.67)
P-trend 0.81 0.99 0.28 0.19
1 PY, Person years.
2 Adjusted for age and sex, same data set as multivariable-adjusted data set.
3 Adjusted for: age, sex, BMI, energy intake, consumption of tea, vegetables, fruits, and fish, socioeconomic status, smoking status (current vs. not current), number of cigarettes
per day, number of years of smoking, and family history of gastric cancer.
4 Adjusted for: age, sex, BMI, energy intake, consumption of tea, vegetables, fruits, and fish, socioeconomic status, number of cigarettes per day, number of years of smoking,
and family history of gastric cancer.
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Within foods, acrylamide levels vary greatly, which leads to
nondifferential misclassification of acrylamide intake, which
biases risk estimates toward null. To investigate the extent of
misclassification, we estimated the acrylamide content (by
using mean acrylamide levels of individual reported foods) of
39 Dutch duplicate 24-h meals, which were collected by the
Dutch National Institute for Public Health and the Environ-
ment in 2004, and correlated this to the analytically measured
content, and that rendered a Spearman correlation coefficient
of 0.78 (E.J.M. Konings, J.G.F. Hogervorst, L.J. Schouten, R.A.
Goldbohm, and P.A. van den Brandt, unpublished results). This
indicates that it is feasible to make a sound rank ordering of the
acrylamide intake via a 24-h meal using these mean acrylamide
levels for foods. The acrylamide values in our food database
were derived from foods that were sampled in 2002 and 2005.
They may not be completely representative of the foods that
were on the market in 1986. This will have resulted in non-
differential misclassification of the intake of our cohort, which
will then have led to some underestimation of the true asso-
ciations.Wedid not querywhether the participants bought their
foods or prepared them at home. Of the important acrylamide-
containing foods, French fries weremost likely to be prepared at
home in the NLCS population. However, French fries contrib-
ute relatively little to the acrylamide intake and to the variance
in acrylamide intake in this cohort. Dutch spiced cake, which is
an important acrylamide source in this cohort, was not prepared
at home. The misclassification that may have arisen from this is
probably also nondifferential and would also have biased the
risk estimates toward null. Despite these potential sources of
nondifferential misclassification, acrylamide intake was asso-
ciated with endometrial, ovarian, and renal cell cancer risk in
this cohort (4,5). From this, we infer that if in reality acrylamide
intake is positively associated with gastrointestinal cancers, the
associations will probably be weaker than for endometrial,
ovarian, and renal cell cancer.
It has to be borne in mind that the variation in acrylamide
intake was to a large extent due to Dutch spiced cake and that
coffee was overall the largest dietary source of acrylamide in our
study. However, adjustment for Dutch spiced cake and coffee
intake in the multivariable-adjusted models did not change the
conclusions on the associations between acrylamide intake and
colorectal, gastric, pancreatic, and esophageal cancer risk.
For the effect modification analyses, HR in many small
subgroups were calculated. This makes it likely that some of the
observed significant P-values for effect modification or signifi-
cantly increased HR in subgroups were spurious. Therefore,
they should be interpreted cautiously but deserve further
investigation in other studies. A high level of nonoccupational
physical activity was associated with an increased acrylamide-
associated risk of colorectal and pancreatic cancer, whereas
obese persons had a significantly increased acrylamide-associ-
ated risk of pancreatic and esophageal cancer, although this was
based on few obese cases. These factors thus quite consistently
modified the risk of some gastrointestinal cancers. This could
give support for the hypothesis of glycidamide-mediated gas-
trointestinal carcinogenesis, but physical activity and obesity are
also known to influence hormone levels and may thus modify the
putative hormonal influences of acrylamide.
This study has some clear strengths, apart from the already
mentioned validity and reproducibility of the NLCS FFQ. The
acrylamide intake assessment is an important asset of the present
study.We used acrylamide levels of foods from the Dutchmarket
only and specifically analyzed foods that were relevant for the
NLCS population.
Due to its prospective nature, selection bias is unlikely and
differential recall bias is absent. Furthermore, the association with
acrylamide intake was studied for various subgroups of tumors
that are known to differ with respect to etiology and risk factors.
In conclusion, overall, we found no indications for a positive
association between dietary acrylamide intake and gastrointesti-
TABLE 4 Association between dietary acrylamide intake and pancreatic cancer risk: the NLCS, 1986–1999
Overall Never and former smokers
Cases, n PY,1 n HR (95% CI)2 HR (95% CI)3 Cases, n PY,1 n HR (95% CI)2 HR (95% CI)4
Pancreatic cancer
Acrylamide intake (10 mg/d) 349 48,283 1.05 (0.95–1.15) 1.06 (0.96–1.17) 166 28,680 1.07 (0.94–1.23) 1.07 (0.93–1.24)
Q1 72 9498 Ref (1.00) Ref (1.00) 40 5979 Ref (1.00) Ref (1.00)
Q2 76 9581 1.08 (0.77–1.51) 1.02 (0.72–1.44) 29 6013 0.74 (0.45–1.22) 0.72 (0.43–1.20)
Q3 69 9647 1.01 (0.71–1.43) 0.96 (0.66–1.38) 36 5157 1.15 (0.71–1.85) 1.07 (0.65–1.76)
Q4 63 9800 0.91 (0.64–1.30) 0.87 (0.60–1.27) 29 5645 0.83 (0.51–1.37) 0.73 (0.43–1.26)
Q5 69 9756 0.97 (0.69–1.37) 0.98 (0.68–1.40) 32 5885 0.84 (0.52–1.37) 0.80 (0.48–1.32)
P-trend 0.60 0.75 0.60 0.45
Microscopically verified pancreatic cancer
Acrylamide intake (10 mg/d) 233 48,286 1.02 (0.92–1.13) 1.03 (0.92–1.15) 105 28,683 0.99 (0.84–1.18) 0.99 (0.83–1.19)
Q1 43 9498 Ref (1.00) Ref (1.00) 25 5979 Ref (1.00) Ref (1.00)
Q2 55 9584 1.28 (0.85–1.94) 1.19 (0.78–1.81) 22 6015 0.88 (0.49–1.58) 0.87 (0.47–1.59)
Q3 44 9647 1.03 (0.66–1.59) 0.94 (0.60–1.47) 20 5157 0.93 (0.51–1.71) 0.87 (0.46–1.62)
Q4 45 9801 1.04 (0.67–1.60) 0.98 (0.62–1.54) 20 5646 0.85 (0.47–1.56) 0.76 (0.40–1.45)
Q5 46 9756 1.05 (0.69–1.61) 1.03 (0.66–1.61) 18 5885 0.73 (0.39–1.35) 0.70 (0.37–1.32)
P-trend 0.78 0.84 0.31 0.24
1 PY, Person years.
2 Adjusted for age and sex, same data set as multivariable-adjusted data set.
3 Adjusted for: age, sex, BMI, height, energy intake, consumption of vegetables, fruits, and alcohol, smoking status (current vs. not current), number of cigarettes per day, number
of years of smoking, diabetes, and family history of pancreatic cancer.
4 Adjusted for: age, sex, BMI, height, energy intake, consumption of vegetables, fruits, and alcohol, number of cigarettes per day, number of years of smoking, diabetes, and
family history of pancreatic cancer.
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nal cancer risk. We encourage other researchers to prospectively
investigate the association between dietary acrylamide intake and
colorectal, gastric, esophageal, and pancreatic cancer risk; to
perform subgroup analyses for nonsmokers; and to study effect
modification by factors such as obesity, physical activity, and age.
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